You are here

The Bioibérica Veterinary division is launching Calmurofel®, a new product for the management of feline idiopathic cystitis

18 Sep 2014
Companion Animal Health

Feline idiopathic cystitis is the most frequent cause of urinary tract disease in animals less than 10 years old. It is the result of complex interactions between various bodily systems including the bladder, the nervous system and other external factors.

Cats most likely to suffer from feline idiopathic cystitis are sedentary, have been neutered or splayed, are fed dry food and live with various other cats. These conditions can cause stress and obesity in cats, two of the risk factors in feline idiopathic cystitis. 

Thanks to its exclusive formulation and quality ingredients CALMUROFEL® guarantees 360º action on feline idiopathic cystitis, because the chondroitin sulfate and glucosamine it contains help repair damage to the bladder and re-establish glycosaminoglycan levels, while L-tryptophan reduces stress and anxiety. ORALVISC ® hyaluronic acid reduces lectin levels in the body and aids in weight regulation. 

CALMUROFEL® capsules can be administered whole or opened, adding them to the cat food. Daily administration is recommended for at least 15 days, following the directions for use.

Related News

25 Jan 2021
Companion Animal Health
  • The product is a supplementary food recommended to nurture growing joints in puppies, principally for fast-growing large breeds and in breeds predisposed to hip dysplasia
  • This is the third launch for the joint health area in the last three years, which renews the entire line.
30 Nov 2020
Companion Animal Health
  • This dietary supplement is recommended to protect the joints of large dog breeds
  • The product stands out for its great palatability, convenient dosage and unique composition on the market
14 Sep 2020
Companion Animal Health
  • This completes its Atopivet® range of dermatological products, both orally and topically, which help maintain the skin's integrity and protective barrier
  • There is increasing evidence that shows that the epidermal barrier function is impaired in canine atopic dermatitis